Innovative solutions
    for more effective diagnostics

Presentation

Products

Pathogens

Client Care

Science

IFU

Contact

Blog

NEWS

End of the Legionella V-TesT

December 7, 2017

 

Products Range

NEW-Resist Range

Oxa-48

KPC

RESIST-3 O.O.K.

RESIST-3 O.K.N.

Immunochromatographic Range

Pathogens detection

40/41 Adenovirus

Adenovirus

Clostridium difficile

Cryptosporidium & Giardia

Cryptosporidium

Escherichia coli O157

Rotavirus & 40/41 Adenovirus

Giardia

Helicobacter pylori

Influenza A & B viruses

Legionella

Respiratory Adenovirus

Rotavirus & Adenovirus

Rotavirus

Respiratory Syncytial Virus (RSV)

Streptococcus (group A)

Trypanosoma brucei gambiense (HAT)

Quatro-VeT (Veterinary)

Molecular Range

Leishmania

Pseudomonas aeruginosa

Scientific partners

PARADIS (Biowin)

CCH Fever (EC-FP7)

Chips 4 life (EC-FP7)

Nidiag (EC-FP7)

AquaVir (FP7)

Nareb (FP7)

Euroleish (H2020-MSCA-ITN)

ebolaMoDRAD (IMI-2)

 

Products  >  Human-Field  >  Human African Trypanosomiasis  >  Sciences

• Sensitivity and specificity of HAT Sero-K-SeT, a rapid diagnostic test for serodiagnosis of sleeping sickness cased by Trypanosoma brucei gambiense: a case-control study.

P. Büscher, P. Mertens, T. Leclipteux, Q. Gilleman, D. Jacquet, D. Mumba-Ngoyi, P. Pati Pyana, M. Boelart, V. Lejon

May 9 - 2014

 Rapid diagnostic test for serodiagnosis of sleeping sickness

 

 

• Preliminary evaluation of the diagnostic performance of the HAT Sero K-SeT rapid diagnostic test in Guinea. 

O. Camara, M. Camara, H. Sakande, M. Leno, E. Dama, Q. Gilleman, P. Büscher, B. Bucheton, V. Jamonneau and V. Lejon.

ISCTRC 2013 Khartoum

 Evaluation of HAT Sero K-SeT Rapid Diagnostic Test

 

 

• Rapid Diagnostic Test for Sleeping Sickness.

P. Büscher, Q. Gilleman and V. Lejon

New England Journal of Medecine 14: 1069-70, 2013

http://www.nejm.org/doi/full/10.1056/NEJMc1210373

 

 

• Rapid diagnostic test for neurological infections in central Africa.

C.P. Yansouni, E. Bottieau, P. Lutumba, A.S. Winkler, L. Lynen, P. Büscher, J. Jacobs, P. Gillet, V. Lejon, E. Alirol, K. Polman, J. Utzinger, M.A. Miles, R.W. Peeling, J-J. Muyembe, F. Chappuis and M. Boelart

Lancet Infectious Diseases 13: 546-58, 2013

http://www.ncbi.nlm.nih.gov/pubmed/23623369

Abstract

Infections are a leading cause of life-threatening neuropathology worldwide. In central African countries affected by endemic diseases such as human African trypanosomiasis, tuberculosis, HIV/AIDS, and schistosomiasis, delayed diagnosis and treatment often lead to avoidable death or severe sequelae. Confirmatory microbiological and parasitological tests are essential because clinical features of most neurological infections are not specific, brain imaging is seldom feasible, and treatment regimens are often prolonged or toxic. Recognition of this diagnostic bottleneck has yielded major investment in application of advances in biotechnology to clinical microbiology in the past decade. We review the neurological pathogens for which rapid diagnostic tests are most urgently needed in central Africa, detail the state of development of putative rapid diagnostic tests for each, and describe key technical and operational challenges to their development and implementation. Promising field-suitable rapid diagnostic tests exist for the diagnosis of human African trypanosomiasis and cryptococcal meningoencephalitis. For other infections-eg, syphilis and schistosomiasis-highly accurate field-validated rapid diagnostic tests are available, but their role in diagnosis of disease with neurological involvement is still unclear. For others-eg, tuberculosis-advances in research have not yet yielded validated tests for diagnosis of neurological disease.

 

 

• Sleeping sickness elimination: are we dreaming?

P. Büscher, Q. Gilleman and P. Mertens

CLI, pp22-24, 2013

http://www.cli-online.com/index.php?id=3632

Abstract

Recent sleeping sickness epidemics killed over 400,000 people in less than 20 sub-Saharan African countries. Serological screening of populations at risk and treatment of confirmed patients have drastically reduced the annually reported cases. Elimination seems feasible but only with new control tools and strategies adapted to the new epidemiological situation.

 

 

• Rapid Development of rapid diagnostic tests for surra and sleeping sickness based on recombinant antigens expressed in Pichia pastoris.

S. Rogé, M. Meul, Y. Guisez, Q. Gilleman, T. Simon and P. Büscher

Institute of Tropical Medecine, November, 2012

 Rapid Development of rapid diagnostic test for surra and Sleeping Sickness

 

 

• Development of a rapid Diagnostic Test for detection of sleeping sickness.

Q. Gilleman, P. Mertens and P. Bûscher

Poster Science For Business - BioWin Day, 2012

 Devolpment of a Rapid Diagnostic Test for detection of sleeping sickness

Home   -   Site Map   -   Privacy Policy   -   Contact   -   FAQ                   All rights reserved CorisBioconcept SPRL 1996-2012©                           www.corisbio.com

Web traffic Optimisation
Universem

Design, Programming & hosting
Impact communication